Yahoo Web Search

  1. Ads
    related to MERCK & CO., INC
  1. To keep the lesson grounded in practicality, we'll use ROE to better understand Merck & Co., Inc. (NYSE:MRK). Our data shows Merck has a return on equity of 33% for ...

  2. It looks like Merck & Co., Inc. (NYSE:MRK) is about to go ex-dividend in the next 3 days. Merck's next dividend payment will be US$0.55 per share, on the back of ...

  3. Merck's Keytruda Combination Gets EC Nod for Kidney Cancer

    Zacks via Yahoo FinanceSep 05 13:36 PM

    Merck & Co., Inc. MRK announced that the European Commission has approved the label expansion of its PD-L1 inhibitor, Keytruda, in combination with Pfizer’s PFE Inlyta ( ...

  4. Merck, Pfizer Slide on Pelosi’s ‘Scary’ Drug-Pricing Plan

    Bloomberg via Yahoo FinanceSep 10 14:00 PM

    Drugmakers from Merck & Co. to Pfizer Inc. were under pressure in Tuesday's trading after documents showed House leader Nancy Pelosi's drug pricing plan appears skewed “ ...

  5. Merck Sees Hammer Chart Pattern: Time to Buy?

    Zacks via Yahoo FinanceSep 11 13:24 PM

    Merck & Co., Inc. MRK has been struggling lately, but the selling pressure may be coming to an end soon. What is a Hammer Chart Pattern? A hammer chart pattern is a popular ...

  6. MSFT, Merck & Co. Inc. MRK, The Procter & Gamble Co. PG, United Technologies Corp. UTX and The Coca-Cola Co. KO.

  7. Merck (MRK) closed the most recent trading day at $86.05, moving -0.69% from the previous trading session. Coming into today, shares of the pharmaceutical company had gained 2.73% in the past month.

  8. Top 6 Holdings of Jeremy Grantham's GMO

    GuruFocus.com via Yahoo FinanceSep 05 22:17 PM

    (NASDAQ:MSFT), Apple Inc. (NASDAQ:AAPL), Oracle Corp. (NYSE:ORCL), UnitedHealth Group Inc. (NYSE:UNH), Medtronic PLC (NYSE:MDT) and Merck & Co. (NYSE:MRK). Grantham ...

  9. Par Pharmaceutical, Inc., Endo's operating company, expects to distribute the product through specialty pharmacies beginning this month.

  10. The European Commission granted approvals to Merck MRK and Roche’s RHHBY PD-L1 inhibitors Keytruda and Tecentriq, respectively, and J&J’s JNJ immunology drug Stelara for expanded use.

  1. Ads
    related to MERCK & CO., INC